Ipilimumab: tested in a combination
412 studies: another drug in the study is under test too. Page 2 of 5. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results postedReport a problem
- NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results postedReport a problem
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results postedReport a problem
- Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaCompletedNCT03682276Phase 1/2Results postedReport a problem
- A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CompletedNCT03668119Phase 2Results postedReport a problem
- Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03663166Phase 1/2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerCompletedNCT03651271Phase 2Results postedReport a problem
- Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCCompletedNCT03573947Phase 2Results postedReport a problem
- Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCompletedNCT03570619Phase 2Results postedReport a problem
- Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverCompletedNCT03472586Phase 2Results postedReport a problem
- Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results postedReport a problem
- Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)TerminatedNCT03461952Phase 2Results postedReport a problem
- PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCCompletedNCT03442569Phase 2Results postedReport a problem
- Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaTerminatedNCT03430791Phase 2Results postedReport a problem
- Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCTerminatedNCT03425331Phase 2Results postedReport a problem
- Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results postedReport a problem
- Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results postedReport a problem
- Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaCompletedNCT03367715Phase 2Results postedReport a problem
- Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)CompletedNCT03285321Phase 2Results postedReport a problem
- Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results postedReport a problem
- Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.CompletedNCT03262779Phase 2Results postedReport a problem
- Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCCompletedNCT03256136Phase 2Results postedReport a problem
- Nivolumab Plus Ipilimumab in Thyroid CancerCompletedNCT03246958Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerCompletedNCT03222076Phase 2Results postedReport a problem
- A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedNCT03215706Phase 3Results postedReport a problem
- Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)Active, not recruitingNCT03203473Phase 2Results postedReport a problem
- A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT03195478Phase 1/2Results postedReport a problem
- Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerCompletedNCT03172624Phase 2Results postedReport a problem
- Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)TerminatedNCT03168464Phase 1/2Results postedReport a problem
- Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerCompletedNCT03158129Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results postedReport a problem
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedNCT03143153Phase 3Results postedReport a problem
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results postedReport a problem
- A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCompletedNCT03138512Phase 3Results postedReport a problem
- A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesCompletedNCT03130959Phase 2Results postedReport a problem
- Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaCompletedNCT03117309Phase 2Results postedReport a problem
- Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerCompletedNCT03101566Phase 2Results postedReport a problem
- SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer PatientsCompletedNCT03065179Phase 2Results postedReport a problem
- Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerCompletedNCT03043599Phase 1/2Results postedReport a problem
- Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerCompletedNCT03036098Phase 3Results postedReport a problem
- An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCompletedNCT03029780Phase 2Results postedReport a problem
- An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03001882Phase 2Results postedReport a problem
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02998528Phase 3Results postedReport a problem
- A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedNCT02985957Phase 2Results postedReport a problem
- A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerCompletedNCT02982954Phase 4Results postedReport a problem
- A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabTerminatedNCT02978443Phase 2Results postedReport a problem
- Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results postedReport a problem
- Ipilimumab and Nivolumab in Leptomeningeal MetastasesCompletedNCT02939300Phase 2Results postedReport a problem
- Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT02919683Phase 2Results postedReport a problem
- A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results postedReport a problem
- Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedNCT02899299Phase 3Results postedReport a problem
- Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results postedReport a problem
- Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results postedReport a problem
- Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results postedReport a problem
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCompletedNCT02872116Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersCompletedNCT02869789Phase 4Results postedReport a problem
- A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyCompletedNCT02864251Phase 3Results postedReport a problem
- A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerCompletedNCT02833233Not applicableResults postedReport a problem
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results postedReport a problem
- Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaActive, not recruitingNCT02743819Phase 2Results postedReport a problem
- Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02741570Phase 3Results postedReport a problem
- Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyCompletedNCT02731729Phase 2Results postedReport a problem
- A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results postedReport a problem
- Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results postedReport a problem
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaCompletedNCT02659540Phase 1Results postedReport a problem
- Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerCompletedNCT02659059Phase 2Results postedReport a problem
- Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaActive, not recruitingNCT02656706Phase 2Results postedReport a problem
- An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaActive, not recruitingNCT02648997Phase 2Results postedReport a problem
- Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7CompletedNCT02601014Phase 2Results postedReport a problem
- Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results postedReport a problem
- Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results postedReport a problem
- A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCompletedNCT02545075Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results postedReport a problem
- Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results postedReport a problem
- Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerTerminatedNCT02506114Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedNCT02488759Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results postedReport a problem
- Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaCompletedNCT02428192Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results postedReport a problem
- Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results postedReport a problem
- Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsCompletedNCT02350764Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results postedReport a problem
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results postedReport a problem
- High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryTerminatedNCT02203604Phase 2Results postedReport a problem
- Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT02158520Phase 2Results postedReport a problem
- Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)CompletedNCT02089685Phase 1/2Results postedReport a problem
- Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseCompletedNCT02046733Phase 2Results postedReport a problem
- A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma PatientsCompletedNCT02009397Phase 1/2Results postedReport a problem
- Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results postedReport a problem
- FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerCompletedNCT01896869Phase 2Results postedReport a problem
- HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4Results postedReport a problem
- Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaCompletedNCT01827111Phase 2Results postedReport a problem
- CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant MelanomaTerminatedNCT01740401Phase 2Results postedReport a problem
- Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults postedReport a problem